CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

The announcement means that Ares Management, an asset manager, will become part of the S&P 500 SPX ahead of the three companies announced after Friday's close. Carvana (CVNA), CRH (CRH) and Comfort ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

The Vanguard Growth ETF holds large positions in tech giants like Nvidia, with a healthy splash of diversification.

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics (CRSP) shares have seen considerable movement over the past month, leaving investors assessing what might be driving sentiment around this gene editing pioneer. With no recent ...

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CRISPR Therapeutics AG before investing. In this article, we go over a few key ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Crispr Therapeutics AG ( (CRSP)) has ...